BridgeBio Pharma (BBIO) Capital Expenditures (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.64% |
| Dec 31, 2025 | 286.43% |
| Sep 30, 2025 | -326.46% |
| Jun 30, 2025 | -23.74% |
| Mar 31, 2025 | 617.02% |
| Dec 31, 2024 | -94.24% |
| Mar 31, 2024 | -83.91% |
| Dec 31, 2023 | -41.22% |
| Sep 30, 2023 | 521.85% |
| Jun 30, 2023 | 891.67% |
| Mar 31, 2023 | 192.31% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 98.35% |
| Jun 30, 2022 | -191.50% |
| Mar 31, 2022 | -66.13% |
| Dec 31, 2021 | -60.76% |
| Sep 30, 2021 | 182.55% |
| Jun 30, 2021 | 16.62% |
| Mar 31, 2021 | 145.91% |
| Dec 31, 2020 | -877.96% |
| Sep 30, 2020 | 58.67% |
| Jun 30, 2020 | -92.27% |
| Mar 31, 2020 | 156.27% |
| Dec 31, 2019 | 358.53% |
| Sep 30, 2019 | 359.04% |
| Jun 30, 2019 | -80.56% |
| Mar 31, 2019 | -42.38% |
| Dec 31, 2018 | 22.48% |